This phase I/II trial evaluates the safety and activity of an anti-cancer drug in children with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade glioma..
This trial is treating patients with Relapsed/refractory leukaemia, Neuroblastoma, Sarcoma and High grade gliomas (brain cancers).
This is a Systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults
Other Non-Commercial Sponsor
University of Birmingham
Eligible patients will be assigned to experimental groups dependant on their condition; Leukaemia, Neuroblastoma, Sarcomas and High Grade Glioma. Each group will receive a weekly IV infusion of PEG- BCT-100.
Recruiting Hospitals Read More